ProShare Advisors LLC cut its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 15.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,911 shares of the medical equipment provider’s stock after selling 8,194 shares during the period. ProShare Advisors LLC’s holdings in Hologic were worth $3,624,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in HOLX. Ameriprise Financial Inc. increased its holdings in shares of Hologic by 43.6% during the first quarter. Ameriprise Financial Inc. now owns 3,507,667 shares of the medical equipment provider’s stock valued at $283,067,000 after acquiring an additional 1,065,767 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Hologic by 3.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,294,635 shares of the medical equipment provider’s stock valued at $265,879,000 after buying an additional 123,245 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in Hologic by 6.7% in the 1st quarter. Rockefeller Capital Management L.P. now owns 3,468 shares of the medical equipment provider’s stock valued at $279,000 after purchasing an additional 219 shares in the last quarter. KB Financial Partners LLC purchased a new position in Hologic in the 1st quarter valued at $109,000. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in Hologic by 2.7% in the 1st quarter. Mercer Global Advisors Inc. ADV now owns 102,949 shares of the medical equipment provider’s stock valued at $8,308,000 after purchasing an additional 2,706 shares in the last quarter. 92.64% of the stock is currently owned by institutional investors.
Hologic Trading Up 0.3 %
Shares of HOLX stock opened at $72.00 on Tuesday. The business’s fifty day moving average price is $76.21 and its 200 day moving average price is $79.24. Hologic, Inc. has a 1-year low of $59.78 and a 1-year high of $87.88. The firm has a market capitalization of $17.64 billion, a PE ratio of 37.31 and a beta of 1.01. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.42 and a quick ratio of 3.73.
Wall Street Analysts Forecast Growth
HOLX has been the topic of several analyst reports. TheStreet lowered Hologic from a “b” rating to a “c+” rating in a report on Monday, July 31st. Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Hologic in a report on Tuesday, August 1st. Royal Bank of Canada reduced their price target on Hologic from $87.00 to $85.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 1st. Morgan Stanley reiterated an “equal weight” rating and set a $86.00 price target on shares of Hologic in a report on Tuesday, August 1st. Finally, Raymond James reduced their price target on Hologic from $100.00 to $95.00 and set an “outperform” rating on the stock in a report on Tuesday, August 1st. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Hologic has an average rating of “Moderate Buy” and an average price target of $88.92.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Five stocks we like better than Hologic
- Investing In Automotive Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in EV Charging Stations
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Upcoming IPO Stock Lockup Period, Explained
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.